Open Access

Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status

  • Raquel López-Mejías1,
  • Fernanda Genre1,
  • Belén Sevilla Pérez2,
  • Santos Castañeda3,
  • Norberto Ortego-Centeno2,
  • Javier Llorca4,
  • Begoña Ubilla1,
  • Sara Remuzgo-Martínez1,
  • Verónica Mijares1,
  • Trinitario Pina1,
  • Vanesa Calvo-Río1,
  • Ana Márquez5,
  • José A Miranda-Filloy6,
  • Antonio Navas Parejo7,
  • Marta Conde-Jaldón8,
  • Lourdes Ortiz-Fernández8,
  • Diego Argila9,
  • Maximiliano Aragües9,
  • Esteban Rubio10,
  • Manuel León Luque10,
  • Juan María Blanco-Madrigal11,
  • Eva Galíndez-Aguirregoikoa11,
  • Francisca González Escribano8,
  • J Gonzalo Ocejo-Vinyals12,
  • Javier Martín13,
  • Ricardo Blanco1 and
  • Miguel A González-Gay1Email author
Contributed equally
Arthritis Research & Therapy201517:102

https://doi.org/10.1186/s13075-015-0622-5

Received: 15 January 2015

Accepted: 8 April 2015

Published: 14 April 2015

Abstract

Introduction

A study was conducted to determine whether the human leukocyte antigen (HLA) B alleles are implicated in the susceptibility to Henoch-Schönlein purpura (HSP) in the largest series of Caucasian HSP patients ever assessed for genetic studies.

Methods

The study population was composed of 349 Spanish patients diagnosed with HSP fulfilling the American College of Rheumatology and the Michel et al. classification criteria, and 335 sex and ethnically matched controls. HLA-B phenotypes were determined by sequencing-based typing (SBT) and analyzed by chi-square or Fisher exact test.

Results

A statistically significant increase of HLA-B*41:02 allele in HSP patients when compared with controls was found (8.3% versus 1.5% respectively; P = 0.0001; OR (odds ratio) =5.76 [2.15-19.3]). These results remained statistically significant after adjusting for Bonferroni correction (P = 0.0028). An internal validation also confirmed the susceptibility effect on HSP associated with HLA-B*41:02 (OR = 5.70 [1.98-16.44]). Since a former study described an association between HLA-DRB1*01:03 and HSP susceptibility, we also evaluated the implication of HLA-B*41:02 independently of HLA-DRB1*01:03. Interestingly, the association remained statistically significant (P = 0.0004, OR = 4.97 [1.8-16.9]). No HLA-B association with specific HSP clinical features was found.

Conclusions

Our study indicates that HLA-B*41:02 is associated with the susceptibility to HSP in Spanish patients irrespective of HLA-DRB1 status.

Introduction

Henoch-Schönlein purpura (HSP), also called immunoglobulin-A (IgA) vasculitis, is a leukocytoclastic vasculitis characterized by IgA dominant immune deposits involving mainly the skin but other tissues as well. HSP is more common in children but it is not exceptional in adults [1]. The main feature of this vasculitis is a palpable purpura involving predominantly the lower extremities. Besides skin involvement, HSP often causes joint pain and gastrointestinal complications [2]. Renal manifestations may also be observed in HSP patients, mainly in adults, indicating a poor prognosis of this disorder [2].

HSP has a multifactorial pathology in which a wide variety of pathogens, drugs, and other environmental exposures have been involved [3]. Furthermore, several studies have revealed the relevant role of some genetic variants (including those located in the human leukocyte antigen (HLA) system [4]) in both susceptibility and HSP clinical heterogeneity.

The HLA region includes a group of genes located in chromosome 6 (6p21) that encodes for proteins on the surface of cells that are responsible for regulation of the immune system in humans [5]. HLA has been described as a common genetic component that underlies immune-mediated diseases [6], being associated with more diseases than any other region of the human genome [5]. In this regard, the association between class II HLA genes and HSP susceptibility in Caucasians has been well-established in a recent well-powered study [4]. In this work, the susceptibility effect of HLA-DRB1*01 (mainly due to HLA-DRB1*01:03 allele) was confirmed, whereas a potential protective effect of HLA-DRB1*03 (mainly due to HLA-DRB1*03:01 allele) was also postulated [4]. However, the influence of class I HLA genes in HSP Caucasian patients still remains unclear since only a few studies, performed in small cohorts of HSP patients, have addressed this issue [7-10]. Although no association between class I HLA (HLA-A, HLA-B, and HLA-C) genes and HSP was found by Ostergaard et al. [10], HLA-B*35 allele has been suggested to be a potential marker of renal complications secondary to HSP by Nathwani et al., Nyulassy et al. and Amoli et al. [7-9].

Taken together these considerations prompted us to investigate the potential implication of HLA-B gene in the susceptibility to HSP. For this purpose we took advantage of the largest series of Caucasian patients with this vasculitis ever assessed for genetic studies.

Methods

Patients and study protocol

A series of 349 Spanish patients with cutaneous vasculitis who fulfilled Michel et al. [11]. classification criteria for HSP were included in the present study. According to these criteria, they were classified as having HSP if they fulfilled three or more of the following characteristics: palpable purpura, bowel angina, gastrointestinal bleeding, macroscopic or microscopic hematuria, age at disease onset ≤20 years, and no previous history of medications prior to the onset of the disease. Also, all patients included in this series were required to fulfill the American College of Rheumatology classification criteria for HSP [12]. Blood samples were obtained from patients recruited from Hospital Universitario Lucus Augusti (Lugo), Hospital Universitario Marqués de Valdecilla (Santander), Hospital Universitario La Princesa (Madrid), Hospital Universitario San Cecilio (Granada), Hospital Universitario Virgen del Rocío (Sevilla) and Hospital Universitario de Basurto (Bilbao). Information on the main clinical features of the whole series of 349 HSP Spanish patients recruited in this study is shown in Table 1. Hematuria with or without proteinuria and severe gastrointestinal manifestations were frequently observed in these patients. However, only 24 of the 349 patients (6.8%) had persistent renal involvement (renal sequelae) at last follow-up.
Table 1

Main clinical features of a series of 349 Spanish patients with HSP

Main characteristics

% (n/N)

Children (age ≤20 years)/adults (age >20 years)

283/66

Male/female

176/173

Age at the onset of the disease (years)

 

mean ± SD

14.8 ± 18.0

median (IQR)

7 (5 to 18)

Duration of follow-up (years, mean ± SD)

3.3 ± 4.3

Palpable purpura and/or maculopapular rash

100 (349/349)

Arthralgia and/or arthritis

56.4 (197/349)

Gastrointestinal manifestations (if ‘a’ and/or ‘b’)

53.6 (187/349)

a) Bowel angina

52.1 (182/349)

b) Gastrointestinal bleeding

16.0 (56/349)

Renal manifestations (if any of the following characteristics)

35.5 (124/349)

a) Hematuria

34.6 (121/349)

b) Proteinuria

32.9 (115/349)

c) Nephrotic syndrome

4.3 (15/349)

d) Renal sequelae (persistent renal involvement)a

6.8 (24/349)

aAt last follow-up. HSP: Henoch-Schönlein purpura; SD: standard deviation; IQR: interquartile range.

A set of 335 sex and ethnically matched controls without history of cutaneous vasculitis or any other autoimmune disease comprising blood donors from the National DNA Bank Repository (Salamanca, Spain), was also included in the study.

A subject’s written consent was obtained according to the declaration of Helsinki, and the study was approved by the Ethics Committees of Galicia for Hospital Universitario Lucus Augusti, of Cantabria for Hospital Universitario Marqués de Valdecilla, of Madrid for Hospital Universitario La Princesa, of Andalucía for Hospital Universitario San Cecilio and Hospital Universitario Virgen del Rocío, and of País Vasco for Hospital Universitario de Basurto.

Genotyping

High-molecular-weight genomic DNA was extracted from whole blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.

All DNA samples were stored at −20°C until the HLA analysis. Class I HLA B locus high-resolution typing was performed through sequencing-based typing (SBT), by using the SBTexcellerator Kit and analyzed with the SBTengine®-SBT HLA typing software (GenDx, Utrecht, The Netherlands) following the manufacturer’s instructions.

Positive controls were used to ensure the quality control for the genotyping procedures. These samples, of known sequence, were obtained from External Proficiency Testing Programs (GECLID – Spanish Society of Immunology), following the European Federation of Immunogenetics standards. Additionally, negative controls were included to discard the effect of DNA contamination.

Statistical analysis

Continuous data are described as mean and standard deviation (mean ± SD) and categorical variables as percentages.

The strength of association between HSP and HLA-B phenotypes was estimated using odds ratios (OR) and 95% confidence intervals (CI). Levels of significance were determined using contingency tables by either the chi-square test or Fisher exact (expected values below 5) analysis. Results were adjusted for Bonferroni correction. To obtain an internal validation, we carried out a bootstrap test with 1,000 replications.

All analyses were performed with STATA statistical software 12/SE (Stata Corp., College Station, TX, USA).

The linkage disequilibrium between HLA alleles was calculated using the PLINK software [13].

Results

When HSP patients were compared with matched controls, some differences in HLA-B phenotype frequencies were observed (Table 2). In this regard, the HLA-B*41 phenotype was significantly increased in HSP patients compared to controls (10.1% versus 3.3%, respectively; P = 0.0007; OR = 3.18 (1.53 to 7.07)). This association was mainly due to the HLA-B*41:02 allele (8.3% in HSP patients versus 1.5% in controls; P = 0.0001; OR = 5.76 (2.15 to 19.3)) and remained statistically significant after adjusting for Bonferroni correction (P = 0.0028) (Table 2). Since the potential effect of HLA-B*41:02 on HSP had not previously been reported, we carried out a bootstrapping procedure that confirmed the susceptibility effect on HSP associated with HLA-B*41:02 (OR = 5.70 (1.98 to 16.44)). However, no statistically significant results were observed regarding other HLA-B phenotypes and HSP susceptibility (Table 2).
Table 2

HLA-B phenotype frequencies in patients with HSP and controls

HLA-B

Patients with HSP (number = 349)

Controls (number = 335)

P

OR (95% CI)

B*07

B*07:02

52 (14.9)

49 (14.6)

0.92

1.02 (0.65 to 1.60)

B*08

B*08:01

29 (8.3)

31 (9.2)

0.66

0.88 (0.50 to 1.56)

B*13

B*13:02

7 (2.0)

8 (2.4)

0.73

0.84 (0.25 to 2.67)

B*14

B*14:01

8 (2.3)

5 (1.5)

0.44

1.54 (0.44 to 6.07)

 

B*14:02

29 (8.3)

47 (14.0)

0.017

0.55 (0.33 to 0.93)

B*15

B*15:01

25 (7.2)

22 (6.6)

0.76

1.10 (0.58 to 2.10)

 

B*15:17

4 (1.2)

5 (1.5)

0.69

0.76 (0.15 to 3.60)

B*18

B*18:01

36 (10.3)

41 (12.2)

0.42

0.82 (0.49 to 1.36)

B*27

B*27:05

20 (5.9)

20 (6.0)

0.89

0.96 (0.48 to 1.91)

B*35

B*35:01

50 (14.3)

51 (15.2)

0.74

0.93 (0.59 to 1.45)

 

B*35:03

20 (5.7)

8 (2.4)

0.027

2.48 (1.02 to 6.61)

B*38

B*38:01

10 (3.0)

27 (8.1)

0.0027

0.34 (0.14 to 0.73)

B*39

B*39:01

8 (2.4)

7 (2.1)

0.85

1.10 (0.34 to 3.61)

B*40

B*40:01

16 (4.6)

17 (5.1)

0.76

0.89 (0.42 to 1.93)

 

B*40:02

10 (3.0)

5 (1.5)

0.22

1.94 (0.59 to 7.33)

B*41 a

B*41:01

6 (1.8)

6 (1.8)

0.94

0.95 (0.25 to 3.62)

 

B*41:02

28 (8.3)

5 (1.5)

0.0001

5.76 (2.15 to 19.3)

B*44

B*44:02

35 (10.0)

16 (4.8)

0.009

2.22 (1.17 to 4.39)

 

B*44:03

61 (17.5)

71 (21.2)

0.22

0.79 (0.53 to 1.17)

B*45

B*45:01

7 (2.0)

11 (3.3)

0.29

0.60 (0.19 to 1.73)

B*49

B*49:01

24 (7.2)

34 (10.1)

0.12

0.65 (0.36 to 1.16)

B*50

B*50:01

26 (7.7)

16 (4.8)

0.14

1.60 (0.81 to 3.26)

B*51

B*51:01

53 (15.2)

56 (16.7)

0.59

0.89 (0.58 to 1.37)

B*52

B*52:01

5 (1.5)

11 (3.3)

0.11

0.43 (0.11 to 1.35)

B*53

B*53:01

12 (3.6)

13 (3.9)

0.76

0.88 (0.36 to 2.13)

B*55

B*55:01

4 (1.2)

12 (3.6)

0.035

0.31 (0.07 to 1.04)

B*57

B*57:01

22 (6.3)

12 (3.6)

0.10

1.81 (0.84 to 4.10)

B*58

B*58:01

13 (3.7)

11 (3.3)

0.75

1.14 (0.46 to 2.85)

a10.1% in HSP patients versus 3.3% in controls; P = 0.0007; OR = 3.18 (1.53 to 7.07); values are expressed as number (n) and percentages (%); the result that remained statistically significant after adjusting for Bonferroni correction (pBNF = 0.0028) is highlighted in bold. HLA: human leukocyte antigen; HSP: Henoch- Schönlein purpura; OR: odds ratio; CI: confidence interval.

Since in a recent study we disclosed an association between HLA-DRB1*01:03 and HSP susceptibility [4], we also evaluated whether the implication of HLA-B*41:02 was independent of the HLA-DRB1*01:03 status (Table 3). Interestingly, and as shown in Table 3, the association of HLA-B*41:02 with HSP susceptibility remained statistically significant irrespective of HLA-DRB1*01:03 (P = 0.0004, OR = 4.97 (1.8 to 16.9)) (Table 3). To further confirm the independence of both alleles, we calculated the linkage disequilibrium between them in our study population. As expected, the r2 value showed that both alleles were independent (r2 = 0.003).
Table 3

HLA-B*41:02 and HLA-DRB1*01:03 are independently associated with increased susceptibility to HSP

HLA-DRB1*01:03

HLA-B*41:02

Patients with HSP

Controls

P

OR (95% CI)

-

-

270

292

-

Ref.

-

+

23

5

0.0004

4.97 (1.8 to 16.9)

+

-

48

6

<0.001

8.65 (3.6 to 25.1)

+

+

1

0

0.2988

-

HLA: human leukocyte antigen; HSP: Henoch- Schönlein purpura; OR: odds ratio; CI: confidence interval.

In a further step we assessed whether HLA-B phenotype differences might exist according to specific features of the disease, such as age at disease onset before and after 20 years, presence of joint, gastrointestinal or renal manifestations. In this regard, we did not observe any trend toward significance between different HLA-B phenotypes and gastrointestinal manifestations. Regarding age at disease diagnosis, we only found a statistically marginal increase in the frequency of adults (>20 years old) carrying the HLA-B*45:01 allele. However, this marginal significance was lost after Bonferroni correction. A statistically significant increase in HLA-B*14:02 and 53:01 was detected in HSP patients with renal manifestations (P = 0.0113 and 0.0415, respectively). However, similarly to the previous case, when we corrected these results by Bonferroni, this significance was lost.

Finally, 12 HSP patients with renal manifestations carried the HLA-B*41:02 allele. However, no statistically significant association was observed between the presence of this HLA-B allele and the presence of renal manifestations (P = 0.513; OR = 1.31 (0.53 to 3.17)).

Discussion

The vasculitides constitute a heterogeneous group of diseases that have in common the presence of inflammation of the blood vessels [1,14]. Their complex etiology is far from being completely elucidated. Both environmental and genetic factors appear to influence the development and progression of these conditions, HLA being the main genetic factor related to these diseases. Although the effect of the class II HLA genes in the susceptibility of HSP in Caucasians has recently been characterized [4], there is scarce information on the potential implication of class I HLA genes in HSP [7-10]. Because of that, we have performed a study to provide evidence of the potential implications of the HLA-B gene in the susceptibility to HSP. For this purpose, we recruited the largest series of Caucasian patients with this vasculitis ever assessed for genetic studies. Accordingly, our findings support the role of the HLA-B*41:02 as a susceptibility marker of this disease irrespective of HLA-DRB1 status. However, in contrast to previous studies [7-9], we could not confirm an association between HLA-B alleles and renal manifestations or any other specific features of this vasculitis. In this regard, considering that our analysis was performed in a well-powered cohort of HSP patients, we cannot exclude the possibility that previous results might have been the result of a type I error. Because of that, additional studies including large series of patients are needed to fully establish the association of the HLA-B locus with specific features of HSP.

Class I HLA molecules have previously been associated with different types of primary systemic vasculitis in Caucasians. An association of HLA-B*15, HLA-B*8, HLA-Cw3 and HLA-Cw6 with giant cell arteritis (a large-sized blood vessel vasculitis) has been reported [15-17]. Although the involvement of class I HLA genes in Kawasaki disease (a vasculitis involving medium-sized blood vessels) is controversial, HLA-B*51 and HLA-B*44 have been proposed to be associated with this disease [18,19]. Additionally, HLA-B*50 has been shown to be related to susceptibility to granulomatosis with polyangiitis, a small-sized vessel anti-neutrophil cytoplasmic antibody-associated vasculitis [20]. Finally, a recently published analysis of imputed genome wide association study data described an association between a genetic variant located between the HLA-B and MICA loci and Behçet’s disease [21]. Regarding HLA-B*35:03, other authors reported an increase of this allele in overall HSP [22]. Even if in our study we observed a significantly increased frequency of this allele in our HSP cohort, this significance was lost after Bonferroni correction. However, this lack of significance after correction in our study might be due to sample size or also to differences between our cohort and that studied by Peru et al. [22].

Conclusions

The analysis of our data supports an association of HLA-B*41:02 with susceptibility to HSP in Caucasians, irrespective of HLA-DRB1 status. These results may have potential clinical implications as they may help to better identify individuals at risk for this vasculitis.

Notes

Abbreviations

CI: 

confidence interval

HLA: 

Human Leukocyte Antigen

HSP: 

Henoch-Schönlein purpura

IgA: 

immunoglobulin-A

IQR: 

interquartile range

OR: 

odds ratio

SBT: 

sequencing-based typing

SD: 

standard deviation

Declarations

Acknowledgements

We wish to thank all the patients with HSP and controls who participated to make this study possible. We want to specially thank Patricia Fuentevilla Rodríguez, María Del Camino Villa Llamazares and María Eugenia Cuadrado Mantecón for their technical assistance. This study was supported by a grant from ‘Fondo de Investigaciones Sanitarias’ PI12/00193 (Spain). RLM is a recipient of a Sara Borrell postdoctoral fellowship from the Instituto de Salud Carlos III at the Spanish Ministry of Health (Spain) (CD12/00425). FG and BU are supported by funds from the RETICS Program (RIER) (RD12/0009/0013).

Authors’ Affiliations

(1)
Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL
(2)
Medicine Department, Hospital Universitario San Cecilio
(3)
Rheumatology Department, Hospital Universitario La Princesa, IIS-Princesa
(4)
Epidemiology and Computational Biology Department, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL
(5)
Institute of Parasitology and Biomedicine López-Neyra (IPBLN-CSIC) and Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio
(6)
Division of Rheumatology, Hospital Universitario Lucus Augusti
(7)
Nephrology Department, Hospital Universitario San Cecilio
(8)
Immunology Department, Hospital Universitario Virgen del Rocío
(9)
Dermatology Department, IIS-IP, Hospital de la Princesa
(10)
Rheumatology Department, Hospital Universitario Virgen del Rocío
(11)
Rheumatology Department, Hospital Universitario de Basurto
(12)
Immunology Department, Hospital Universitario Marqués de Valdecilla
(13)
Institute of Parasitology and Biomedicine López-Neyra, CSIC

References

  1. González-Gay MA, García-Porrúa C. Epidemiology of the vasculitides. Rheum Dis Clin North Am. 2001;27:729–49.View ArticlePubMedGoogle Scholar
  2. García-Porrúa C, Calviño MC, Llorca J, Couselo JM, González-Gay MA. Henoch-Schönlein purpura in children and adults: clinical differences in a defined population. Semin Arthritis Rheum. 2002;32:149–56.View ArticlePubMedGoogle Scholar
  3. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402–14.View ArticlePubMedGoogle Scholar
  4. López-Mejías R, Genre F, Pérez BS, Castañeda S, Ortego-Centeno N, Llorca J, et al. HLA-DRB1 association with Henoch-Schonlein purpura. Arthritis Rheumatol. 2015;67:823–7.View ArticleGoogle Scholar
  5. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature. 1999;401:921–3.View ArticleGoogle Scholar
  6. Klein J, Sato A. The HLA system, second of two parts. N Engl J Med. 2000;343:782–6.View ArticlePubMedGoogle Scholar
  7. Amoli MM, Thomson W, Hajeer AH, Calviño MC, Garcia-Porrua C, Ollier WE, et al. HLA-B35 association with nephritis in Henoch-Schonlein purpura. J Rheumatol. 2002;29:948–9.PubMedGoogle Scholar
  8. Nathwani D, Laing RB, Smith CC, Edward N. Recurrent post-infective Henoch-Schonlein syndrome: a genetic influence related to HLA B35? J Infect. 1992;25:205–10.View ArticlePubMedGoogle Scholar
  9. Nyulassy S, Buc M, Sasinka M, Pavlovic M, Slugen I, Hirschová V, et al. The HLA system in glomerulonephritis. Clin Immunol Immunopathol. 1977;7:319–23.View ArticlePubMedGoogle Scholar
  10. Ostergaard JR, Storm K, Lamm LU. Lack of association between HLA and Schoenlein-Henoch Purpura. Tissue Antigens. 1990;35:234–5.View ArticlePubMedGoogle Scholar
  11. Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis and Henoch-Schonlein purpura: a comparison between the 2 disorders. J Rheumatol. 1992;19:721–8.PubMedGoogle Scholar
  12. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum. 1990;33:1114–21.View ArticlePubMedGoogle Scholar
  13. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75.View ArticlePubMed CentralPubMedGoogle Scholar
  14. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11.View ArticlePubMedGoogle Scholar
  15. Armstrong RD, Behn A, Myles A, Panayi GS, Welsh KI. Histocompatibility antigens in polymyalgia rheumatica and giant cell arteritis. J Rheumatol. 1983;10:659–61.PubMedGoogle Scholar
  16. Gonzalez-Gay MA, Rueda B, Vilchez JR, Lopez-Nevot MA, Robledo G, Ruiz MP, et al. Contribution of MHC class I region to genetic susceptibility for giant cell arteritis. Rheumatology (Oxford). 2007;46:431–4.View ArticleGoogle Scholar
  17. Kemp A, Marner K, Nissen SH, Heyn J, Kissmeyer-Nielsen F. HLA antigens in cases of giant cell arteritis. Acta Ophthalmol (Copenh). 1980;58:1000–4.View ArticleGoogle Scholar
  18. Kaslow RA, Bailowitz A, Lin FY, Koslowe P, Simonis T, Israel E. Association of epidemic Kawasaki syndrome with the HLA-A2, B44, Cw5 antigen combination. Arthritis Rheum. 1985;28:938–40.View ArticlePubMedGoogle Scholar
  19. Krensky AM, Berenberg W, Shanley K, Yunis EJ. HLA antigens in mucocutaneous lymph node syndrome in New England. Pediatrics. 1981;67:741–3.PubMedGoogle Scholar
  20. Cotch MF, Fauci AS, Hoffman GS. HLA typing in patients with Wegener granulomatosis. Ann Intern Med. 1995;122:635.View ArticlePubMedGoogle Scholar
  21. Hughes T, Coit P, Adler A, Yilmaz V, Aksu K, Düzgün N, et al. Identification of multiple independent susceptibility loci in the HLA region in Behcet’s disease. Nat Genet. 2013;45:319–24.View ArticlePubMedGoogle Scholar
  22. Peru H, Soylemezoglu O, Gonen S, Cetinyurek A, Bakkaloğlu SA, Buyan N, et al. HLA class 1 associations in Henoch Schonlein purpura: increased and decreased frequencies. Clin Rheumatol. 2008;27:5–10.View ArticlePubMedGoogle Scholar

Copyright

© López-Mejías et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement